ニュース＆コラム | Laminar IP - Patent and Trade Mark Attorneys

•August 19, 2026

Manner of Manufacture After Aristocrat: Analysis of CQMS Pty Ltd v Joy Global Surface Mining Inc [2026] APO 19

Technical Monitoring vs Economic Decision-Making: Where the Patentable Subject Matter Line Is Drawn

•June 8, 2026

Patentable Subject Matter in Australia

Principles of “manner of manufacture” and characterization of the invention.

•June 2, 2026

Laminar IP Opens New Office in Bangkok, Thailand

Laminar IP has officially opened a new office in Bangkok, establishing a direct, on-the-ground presence in Thailand.

•May 30, 2026

Award: Laminar IP recognised in IAM Patent 1000 (2026) – Bronze for Firm and both Founding Partners

Laminar IP and Founding Partners Jiarne Hong and Mark Teoh once again recognised as leaders in IAM Patent 1000 (2026).

•May 27, 2026

ニュージーランドにおける分割出願の注意点

ニュージーランドの特許の分割出願の要件は、日本と大きく異なるため注意が必要です。本記事では、ニュージーランドにおける分割出願の注意点について説明します。

•May 27, 2026

Zip Co v Firstmac: High Court Recalibrates the Honest Concurrent Use Defence

Australia’s High Court tightens the honest concurrent use defence, making early trade mark clearance and prompt action critical for brand owners.

•May 12, 2026

NOCO v Brown & Watson Lights Up Australia’s ‘Best Method’ Requirement for Divisionals

The Full Federal Court in NOCO v Brown & Watson confirms Australia’s “Best Method” requirement, raising the stakes for parent drafting and portfolio strategy.

•May 8, 2026

オーストラリアにおける医薬製剤の特許権の存続期間の延長（PTE）― Otsuka v Sun Pharma 判決後の状況

オーストラリア高等裁判所、医薬品特許の特許期間の延長（PTE）の命運を握る判断へ―（再）製剤の特許はPTEの対象となるか。

•May 8, 2026

Patent Term Extensions for Pharmaceutical Formulations in Australia after Otsuka v Sun Pharma

Australia’s High Court to Decide the Fate of Pharmaceutical Patent Term Extensions (PTEs) —(re)Formulation?

ご質問やサポートが必要な場合は、お気軽にご連絡ください。

お問い合わせ